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Perspective
T
raumatic brain injury (TBI) 
is a major cause of death and 
disability throughout the world. 
The annual incidence of TBI in the 
United States has been estimated at 
between 180 and 250 per 100,000 
population per year [1]. TBI is the 
cause of one third to one half of all 
trauma deaths, and the leading cause 
of disability in people under 40, 
severely disabling 15 to 20 per 100,000 
population per year [2]. Injuries, 
including TBI, are projected to account 
for 20% of the worldwide burden of 
death and disability by 2020 [3].
Research into new therapies for TBI 
has been disappointing. At least 21 
multi-centre clinical trials have been 
conducted since 1985, none of which 
have shown a convincing benefit in 
the treatment of TBI [4]. Clinical trials 
into TBI provide significant challenges: 
trauma is a neglected research topic 
worldwide, consent in unconscious 
patients requires careful ethical 
consideration, and the injuries are very 
heterogeneous in terms of mechanism 
and pathology [4,5]. 
Prognostic Models
Prognostic models are statistical models 
that combine data from patients to 
predict clinical outcome. Such models 
based on data collected soon after 
presentation could in theory be used to 
aid early clinical decision making and 
to allow more accurate counselling of 
patients’ families. They could also have 
a pivotal role in the future design and 
analysis of randomised controlled trials, 
and assist in clinical audit by allowing 
adjustment for case mix [5]. 
However, while many prognostic 
models have been developed, none 
are widely used. A recent systematic 
review of prognostic models in TBI 
found that they were developed from 
small samples of patients, had poor 
methodology (for example, in over 
half of the models, loss to follow-up was 
not reported), were rarely externally 
validated, and were not clinically 
practical [5].
Developing a New Prognostic 
Model for TBI
In recent years, there have been 
two milestones that helped forward 
research into TBI: the formation of 
the IMPACT (International Mission on 
Prognosis and Analysis of Clinical Trials 
in TBI) database [4], and the CRASH 
(Corticosteroid Randomisation After 
Significant Head Injury) trial [6]. The 
IMPACT database combined patient 
data from eight randomised controlled 
clinical trials and three observational 
studies to give a patient population 
of over 9,000. The CRASH trial was 
a randomised controlled trial of the 
effect of early steroid administration 
on outcome after TBI. The CRASH 
trial enrolled 10,008 patients and is the 
largest clinical trial ever conducted in 
patients with TBI.
This year, the CRASH trial 
collaborators published in the BMJ
a series of prognostic models for 
predicting outcome after TBI, based 
on the 10,008 patients enrolled in the 
CRASH trial [7]. As well as being the 
largest prognostic models developed 
for TBI, the new models display other 
key differences from previous models: 
they were externally validated, included 
patient data from low- and middle-
income countries, and are publicly 
available. The external validation for 
these models took place against patient 
data in the IMPACT database.
In a paper published in this issue of 
PLoS Medicine, Ewout Steyerberg and 
colleagues describe the development 
and validation of new prognostic 
models for TBI [8]. The authors review 
patient characteristics from 8,509 
patients in the IMPACT database. 
From an initial examination of 26 
potential predictors, the authors define 
a core prognostic model based on 
three clinical predictors: age, motor 
component of Glasgow coma score 
(GCS), and pupillary reactivity. They 
also develop an extended model, which 
Developing a Prognostic Model for Traumatic 
Brain Injury—A Missed Opportunity?
Neil H. Young, Peter J. D. Andrews*
The Perspective section is for experts to discuss the 
clinical practice or public health implications of a 
published article that is freely available online.
Funding: The authors received no specific funding 
for this article. 
Competing Interests: NHY declares that he 
has no competing interests. PJDA declares 
that he is a researcher in traumatic brain injury 
and Chief Investigator of the EUROTHERM Trial 
(ISRCTN34555414; http://www.controlled-trials.com/
ISRCTN34555414).
Citation: Young NH, Andrews PJD (2008) Developing
a prognostic model for traumatic brain injury—A 
missed opportunity? PLoS Med 5(8): e168. 
doi:10.1371/journal.pmed.0050168
Copyright: © 2008 Young and Andrews. This is an 
open-access article distributed under the terms 
of the Creative Commons Attribution License, 
which permits unrestricted use, distribution, 
and reproduction in any medium, provided the 
original author and source are credited.
Abbreviations: CRASH, Corticosteroid 
Randomisation After Significant Head Injury; GCS, 
Glasgow coma scale; GOS, Glasgow outcome scale; 
IMPACT, International Mission on Prognosis and 
Analysis of Clinical Trials in TBI; TBI, traumatic brain 
injury
Neil H. Young and Peter J. D. Andrews are in the 
Department of Anaesthesia, Critical Care and Pain 
Medicine, Western General Hospital, Edinburgh, 
United Kingdom.
* To whom correspondence should be addressed. 
E-mail: P.Andrews@ed.ac.uk
Linked Research Article
This Perspective discusses the 
following new study published in PLoS
Medicine:
Steyerberg EW, Mushkudiani N, 
Perel P, Butcher I, Lu J, et al. (2008) 
Predicting outcome after traumatic brain 
injury: Development and international 
validation of prognostic scores based on 
admission characteristics. PLoS Med 5(8): 
e165. doi:10.1371/journal.pmed.0050165
Ewout Steyerberg and colleagues 
describe a prognostic model for the 
prediction of outcome of traumatic brain 
injury using data available on admission.PLoS Medicine  |  www.plosmedicine.org 1187 August 2008  |  Volume 5  |  Issue 8  |  e168
includes the three core predictors 
plus information on secondary insults 
and computerized tomography 
characteristics, and a laboratory model, 
which also includes haemoglobin and 
glucose measurement. 
The endpoint was Glasgow outcome 
scale (GOS) at six months (the GOS 
runs from 1 to 5, with 1 representing 
death and 5 representing recovery; 
see http://www.dundee.ac.uk/
medther/Stroke/Scales/Gos.htm).
For validation, the authors focus on 
prediction of death (GOS 1) versus 
survival (GOS 2–5) and of unfavourable 
(GOS 1–3) versus favourable (GOS 
4–5) outcome. The model was 
externally validated on data from 6,272 
patients from the CRASH trial. All 
predictors had statistically significant 
associations with six-month GOS. The 
discriminatory ability of the models 
was shown to increase with increasing 
complexity. External validation 
confirmed the discriminatory ability 
of the core model and a modified 
computerized tomography model with 
6,681 and 5,309 patients, respectively, 
from the CRASH trial. The calibration 
was not as good, in that outcomes from 
the CRASH trial were systematically 
poorer; however, calibration was near 
perfect when only the patients from 
high-income countries were included.
Steyerberg and colleagues’ paper 
in PLoS Medicine and the recent BMJ
paper use very similar methodology 
to develop their predictive models 
(one used the IMPACT dataset as the 
training dataset and the other the 
CRASH dataset, externally validating 
against the other). It is debatable 
whether publishing two papers 
separately added value—they could 
have possibly been combined in a 
single publication.
What Are the Strengths and 
Limitations of This Model?
While the predictors of age, motor 
score, and pupillary reactivity have 
been included in many prognostic 
models for TBI, Steyerberg and 
colleagues’ models [8] and the models 
produced by the CRASH collaborators 
[7] are the largest and most robustly 
validated that have been developed so 
far. They are also readily accessible to 
clinicians via a Web-based calculator 
[9,10].
Caution must be advised in applying 
population-based estimates of outcome 
to individual patients. While both of 
these groups of prognostic models have 
been externally validated, they have 
essentially been validated against the 
populations of each other. All of the 
patients from CRASH and most of the 
patients from IMPACT were enrolled 
in clinical trials. Work is needed to 
establish the accuracy of these models 
prospectively in patients not enrolled in 
clinical trials.
The CRASH dataset is more 
heterogeneous than many of the phase 
III neuroprotection studies because 
inclusion GCS included moderate 
and severe injury and included a high 
number of patients from low- and 
middle-income countries. Steyerberg 
and colleagues’ models seemed 
less accurate at predicting outcome 
following TBI in low- and middle-
income countries. 
Logistic regression, used in the PLoS
Medicine and BMJ papers [7,8], treats 
the patient cohorts as homogeneous 
and therefore has a number of 
limitations. In contrast, decision tree 
analysis takes a group of subjects and 
divides them into subgroups according 
to the best discriminating factor within 
the original group. The level at which 
each discriminating factor (blood 
pressure, age, GCS, gender, etc.) is 
important is given, and the process 
is repeated recursively producing 
subgroups with less variability or 
entropy than the original. If followed 
to the conclusion of the process, each 
patient would end up in a category 
of his or her own, a situation that is 
closer to clinical reality than treating 
all patients as a homogenous group 
and thus the same. Decision tree 
analysis requires a finite number of 
target categories to be of value. Logistic 
regression analysis was previously 
compared with decision tree analysis 
for predicting recovery from traumatic 
brain injury, using a small dataset from 
124 adult head-injured patients in an 
intensive care unit [11]. 
Comparison between the logistic 
regression analysis and decision tree 
analysis shows a number of similarities, 
particularly that hypotension is a strong 
indicator of bad outcome and that 
age, gender, and brainstem syndromes 
are important indicators. Differences 
include the creation of smaller patient 
groups by the decision tree, each of 
which is characterized, whereas the 
regression analysis suggests factors that 
discriminate for the set of patients as 
a whole [12,13]. Decision tree analysis 
identifies more homogenous subgroups 
and predictors that are important to 
that subgroup. Such subgroups might 
include, for example, a good prognosis 
group with the following discriminating 
factors: young age, extradural 
haematoma, and initial good GCS. A 
possible poor prognosis group might 
be identified as: elderly patients, acute 
subdural haematoma, low GCS, and 
severe comorbidity. It is not plausible 
that the same prognostic factors will 
carry the same importance in such 
disparate categories of TBI. 
The logistic regression analysis and 
decision tree analysis show age is an 
important co-variant in prediction of 
outcome, but the decision tree gives 
threshold values of 50 years for the 
prediction of death and 30 years for 
prediction of good or poor outcome. 
It might be clinically more informative 
to apply decision tree analysis to the 
IMPACT and CRASH datasets for 
prediction and hypothesis generation/ 
revision.
Clinical Implications
We now have new prognostic models 
for TBI developed from large 
numbers of patients, which have been 
externally validated to allow prediction 
between favourable or unfavourable 
outcome at six months [7,8]. These 
models may provide useful additional 
information in regard to clinical 
decision making and the counselling 
of patients’ relatives, but it must be 
remembered that their outcomes 
apply to populations—and so great 
caution is needed if applying them 
to individual patients. These models 
will undoubtedly be of great use in 
clinical audit, allowing comparison 
between different units and changes in 
management over time, while allowing 
for different case mix. The models 
should also allow better trial design 
and analysis: many patients with TBI 
previously included in clinical trials 
have expected outcomes that are so 
good or bad that no intervention could 
be expected to alter the outcome [14]. 
Future clinical trials could focus on 
those patients with a more uncertain 
prognosis.  
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